树突状细胞疫苗对黑色素瘤患者免疫功能的影响

发布时间：2017-12-28 08:59

本文关键词：树突状细胞疫苗对黑色素瘤患者免疫功能的影响　出处：《医学与哲学(B)》2016年07期 　论文类型：期刊论文

【摘要】：本文探讨了树突状细胞疫苗治疗黑色素瘤患者后外周血T细胞亚群及NK细胞的变化及其意义。树突状细胞疫苗治疗29例黑色素瘤患者,治疗前及治疗4周后分别采外周血运用流式细胞技术检测T淋巴细胞亚群及NK细胞百分比。对检测结果进行比较分析,树突状细胞疫苗治疗4周后外周血T细胞亚群及NK细胞百分比显著高于治疗前的水平,差异有统计学意义(P0.05)。29例患者中CR 1例,PR 16例,有效率58.62%。患者血常规及肝肾功能检测均正常,未出现明显毒副反应。通过研究发现树突状细胞疫苗可明显提高黑色素瘤患者T细胞亚群及NK细胞百分比,明显改善黑色素瘤患者的免疫功能,临床应用无明显不良反应。
[Abstract]:In this paper, the changes and significance of T cell subsets and NK cells in peripheral blood of patients with melanoma treated with dendritic cell vaccine were investigated. Dendritic cells vaccine was used to treat 29 cases of melanoma. Peripheral blood was collected before treatment and 4 weeks after treatment. The percentage of T lymphocyte subsets and NK cells was detected by flow cytometry. The detection results were compared and analyzed. After 4 weeks of dendritic cell vaccine treatment, the percentage of T cell subsets and NK cells in peripheral blood was significantly higher than that before treatment, the difference was statistically significant (P0.05). Of the 29 patients, 1 were CR and 16 were PR, with an effective rate of 58.62%. The patient's blood routine and liver and kidney function were all normal, and no obvious toxic and side effects were found. It is found that dendritic cell vaccine can significantly increase the percentage of T cell subsets and NK cells in melanoma patients, and significantly improve the immune function of melanoma patients. There is no obvious adverse reaction in clinical application.
【作者单位】：中国医科大学肿瘤医院辽宁省肿瘤医院骨软组织肿瘤科;
【基金】：2013年度辽宁省公益基金项目,项目编号:GY2013-A-021
【分类号】：R739.5
【正文快照】：

【相似文献】